Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 21, 2026, 9:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 3,884 matching trials from the live ClinicalTrials.gov search.
Conditions
Prostate Cancer
Interventions
Coronary CT Angiography (CCTA)
Device
Lead sponsor
Indiana University
Other
Eligibility
40 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Carmel, Indiana • Indianapolis, Indiana
Conditions
Prostate Cancer
Interventions
Lower-Carbohydrate Med-t-Diet, Low-Fat Med-t-Diet
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Lymphadenopathy, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Carcinoma Metastatic in the Bone, Prostate Small Cell Carcinoma
Interventions
Cabazitaxel, Carboplatin, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Detroit, Michigan • Houston, Texas
Conditions
Metastatic Castration Sensitive Prostate Cancer (mCSPC)
Interventions
darolutamide plus androgen deprivation therapy, Enzalutamide plus androgen deprivation therapy
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
4,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Conditions
Prostate Cancer
Interventions
carboplatin, estramustine, paclitaxel, radiation therapy, leuprolide or goserelin acetate
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
23
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Worcester, Massachusetts + 12 more
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
ONCT-534
Drug
Lead sponsor
Oncternal Therapeutics, Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
9
States / cities
San Francisco, California • Detroit, Michigan • Omaha, Nebraska + 6 more
Conditions
Prostatic Neoplasms
Interventions
Enzalutamide, NSAA, LHRHA or Surgical Castration
Drug
Lead sponsor
University of Sydney
Other
Eligibility
18 Years and older · Male only
Enrollment
1,125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Prostate Cancer, Polygenic Risk Score
Interventions
Polygenic Risk Score (PRS)
Other
Lead sponsor
Adam S. Kibel, MD
Other
Eligibility
40 Years to 69 Years · Male only
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland • Boston, Massachusetts
Conditions
Prostate Cancer Metastatic Disease, Prostate Cancers
Interventions
FAPI, Positron Emission Tomography (PET), Magnetic Resonance Imaging
Radiation · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Castration-Sensitive Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Small Cell Neuroendocrine Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Antiandrogen Therapy, Abiraterone Acetate, Prednisone, Radiation Therapy
Drug · Radiation
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Prostate Cancer
Interventions
18F-DCFBC
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Prostate Cancer
Interventions
Degarelix, pTVG-AR, Nivolumab, Cemiplimab, Fianlimab, FLT PET/CT
Drug · Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
Interventions
REGN5678, Cemiplimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
24
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 17 more
Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
177Lu-PSMA-617
Drug
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older · Male only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Conditions
Prostate Cancer
Interventions
Docetaxel, CG1940/CG8711
Drug · Biological
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Diagnostic Imaging
Interventions
BAY1075553
Drug
Lead sponsor
Lantheus Biosciences Ltd.
Industry
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Prostate Cancer
Interventions
SU011248
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Orange, California
Completed Not applicable Interventional Results available

Performance Evaluation of the AMS CONTINUUM™ Device

NCT00894933
Conditions
Prostate Cancer
Interventions
CONTINUUM™
Device
Lead sponsor
American Medical Systems
Industry
Eligibility
40 Years and older · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Little Rock, Arkansas • Burlington, Massachusetts • Rochester, New York + 3 more
Conditions
Urothelial Cancer, Bladder Cancer, Genitourinary Cancer, Urogenital Neoplasms, Urogenital Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2042
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 2 Interventional Results available

FACBC PET/CT for Recurrent Prostate Cancer

NCT00562315
Conditions
Prostate Cancer
Interventions
FACBC, ProstaScinct
Drug · Other
Lead sponsor
David M. Schuster, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Diseases, Male, Urogenital Diseases, Male, Prostatic Disease, Prostatic Neoplasms, Castration-Resistant, Prostate Cancer
Interventions
Gedatolisib, Darolutamide
Drug
Lead sponsor
Celcuity Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Stage I Breast Cancer, Stage I Colorectal Cancer AJCC v6 and v7, Stage I Prostate Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage II Colorectal Cancer AJCC v7, Stage II Prostate Cancer, Stage IIA Breast Cancer, Stage IIA Colorectal Cancer AJCC v7, Stage IIA Prostate Cancer, Stage IIB Breast Cancer, Stage IIB Colorectal Cancer AJCC v7, Stage IIB Prostate Cancer, Stage IIC Colorectal Cancer AJCC v7, Stage III Colorectal Cancer AJCC v7, Stage IIIA Colorectal Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7
Interventions
Informational Intervention, Internet-Based Intervention, Quality-of-Life Assessment, Questionnaire Administration, Telephone-Based Intervention
Other · Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
30 Years and older
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
2
States / cities
New Brunswick, New Jersey • Philadelphia, Pennsylvania
Conditions
Prostate Cancer
Interventions
NX-1207 2.5 mg, NX-1207 15 mg
Drug
Lead sponsor
Nymox Corporation
Industry
Eligibility
45 Years to 85 Years · Male only
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
23
States / cities
Tucson, Arizona • Atherton, California • La Mesa, California + 20 more